Storys zum Thema Enterprises

01.09.2008 – 14:43
Society for Cardiovascular Angiography and Interventions (SCAI)
SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Washington (ots/PRNewswire) - - One-Year Data Find Angioplasty and Stenting Safe and Effective in Patients for Whom Standard Therapy Has Been Open-Heart Surgery Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease can safely choose to be treated with angioplasty and drug-eluting stents rather ...
mehr
01.09.2008 – 12:36
Biosensors International
Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study
Munich, Germany (ots/PRNewswire) - Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared to Johnson & Johnson's industry leading ...
mehr
01.09.2008 – 06:35
CHU Montpellier
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
Montpellier, France (ots/PRNewswire) - The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that dronedarone (Multaq(R)) significantly reduces mean 24 hour ventricular rate, on top of other rate control agents. The mean ...
mehr
31.08.2008 – 12:35
Boehringer Ingelheim
First Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The ...
mehr
29.08.2008 – 16:12
Tibotec Pharmaceuticals Ltd.
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Cork, Ireland (ots/PRNewswire) - -INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI-Resistant Virus The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next generation non-nucleoside ...
mehr
28.08.2008 – 19:36
Astellas Pharma Europe Limited
New Research Reveals That Mycamine(R) is an Effective Treatment in Children, Young Babies and Premature Infants
Staines, England (ots/PRNewswire) - - Not for distribution in the United Kingdom - Research Adds to Already Demonstrated Efficacy in Adult Population Parents and paediatricians are today welcoming the results of new research that adds additional support for an effective and well tolerated treatment ...
mehr

27.08.2008 – 00:17
Platts
At Platts Energy Podium, EIA Chief Says Oil 'Could' Fall Below US$100
Washington (ots/PRNewswire) - Crude oil prices "could" fall below US$100 per barrel over the next 18 months on slowing worldwide demand and an increase in oil production, Energy Information Administration (EIA) chief Guy Caruso said Tuesday. Caruso made the comment to reporters at the Platts Energy Podium in Washington. "I think [prices] could fall below US$100 a barrel on slowing global demand and rising ...
mehr
26.08.2008 – 13:20
Algorithme Pharma
After Their U.S. Purchase, Algorithme Pharma Gains a Foothold in Europe Through the Acquisition of a New Clinical Research Location in the United Kingdom
Laval, Canada (ots/PRNewswire) - The Laval-based firm Algorithme Pharma is pleased to announce that it has achieved its goal of securing a European facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only six weeks after confirming the purchase of another clinical ...
mehr
25.08.2008 – 16:12
Resverlogix Corp.
Phase 1b/2a Program Commences for RVX-208
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan. "We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study ...
mehr
25.08.2008 – 14:06
Atmel Corporation
Atmel Targets Low Power Designs With World's First 1.8V 8-Megabit Serial Flash
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) announced today the production availability of its new AT25DF081, the industry's first 8-megabit Serial Flash device capable of operating at 1.8-volts. With a low-voltage operating range of 1.65V to 1.95V, the AT25DF081 operates at the same voltage range as many current and ...
mehr
21.08.2008 – 18:06
ICS Copper Systems Ltd
Appointment of Chairman & New Director to the Board of Directors
Abbotsford, British Columbia (ots/PRNewswire) - ICS Copper Systems Ltd. (ICS) (ICX:TSX.V) is pleased to announce the appointment of Mr. Richard Molyneux to the position of Chairman of the Board of Directors. The Company wishes to express its gratitude to the outgoing Chairman, Mr. Mel Smale, who will stay on as a Director. Mr. Smale has been the Chairman of ICS since the Company went public and has served the ...
mehr
19.08.2008 – 16:19
Eli Lilly and Company
New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
Indianapolis (ots/PRNewswire) - - Study with duloxetine evaluating long-term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic peripheral neuropathic pain (DPNP) for more than six months,(1) according to new ...
mehr

18.08.2008 – 10:15
Mazda (Suisse) SA
Mazda one of Europe's fastest-growing Brands in 2008
Petit-Lancy (ots) - - July retails sales up 28 percent - 220,500 units January-July highest volume in company history - 17 countries up in July, 15 countries with double-digit growth ots Originaltext: Mazda (Suisse) SA Internet: www.presseportal.ch/fr Contact: Mazda (Suisse) SA Giuseppe Loffredo PR Director Tel.: +41/22/719'33'60 E-Mail: gloffredo@mazda.ch Internet: ...
mehr
12.08.2008 – 23:32
Platts
Platts Survey: OPEC Crude Oil Output Rises 300,000 b/d to 32.77 Million Barrels Per Day In July
London (ots/PRNewswire) - Platts -- The Organization of the Petroleum Exporting Countries' (OPEC) 13 members boosted their collective crude oil production by 300,000 barrels per day (b/d) in July to average 32.77 million b/d over the month, according to a Platts survey of OPEC and oil industry officials just released. Excluding Iraq, the 12 members bound by ...
mehr
08.08.2008 – 14:07
Atmel Corporation
Atmel Supports Digital Broadcasting Information Service, Journaline, at the Olympic Games in Beijing
Heilbronn, Germany (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) announced today that it supports a new text-based information service for digital broadcasting, called Journaline(R), which will be integrated into several shuttle vehicles at the 2008 Summer Olympics in China. This service delivers ...
mehr
08.08.2008 – 00:41
Abbott Laboratories
Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Capsule
Mexico City (ots/PRNewswire) - - Pivotal Study of Norvir Tablet Bioavailability Will Form the Basis of Request for Priority Regulatory Review Abbott (NYSE: ABT) presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City today showing that its investigational Norvir(R) ...
mehr
07.08.2008 – 23:12
Premier Muzik International Corporation
Montreal Company Premier Muzik International Corporation Buys an Unreleased Recording by the Beatles in an Internet Auction
Montreal (ots/PRNewswire) - Gino Olivieri, founder of Premier Muzik International Corporation, a Montreal company that administers and redistributes royalties to such artists as Red Hot Chili Peppers, Metallica, Bob Sinclar and Andrea Bocelli, has realized one of his fondest dreams by becoming the winning bidder ...
mehr
07.08.2008 – 02:10
Oremex Resources Inc.
Oremex Update
Vancouver (ots/PRNewswire) - Oremex Resources Inc. (TSX-V: ORM) (the Company) today provided a progress update for the Tejamen Silver Property (Tejamen). The Company has generated significant support for development of Tejamen from State, regional and local officials as well as the commercial, health, educational and regional sectors and the general populace of Tejamen and Nuevo Ideal. In addition, the Federal Minister of Mines has dedicated staff to assist with ...
mehr

05.08.2008 – 21:26
Abbott Laboratories
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Mexico City (ots/PRNewswire) - - HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar ...
mehr
05.08.2008 – 18:25
Tibotec Pharmaceuticals Ltd.
TMC278 Demonstrates Long-Term Efficacy and Tolerability in Treatment-Naïve Adults With HIV
Mexico City, Mexico (ots/PRNewswire) - - Ninety-Six-Week Data on Tibotec Investigational NNRTI Presented at AIDS 2008 New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), provides long-term efficacy and tolerability in treatment-naïve adults ...
mehr
31.07.2008 – 12:41
Roche Pharmaceuticals
MabThera Filed in the EU for Treatment of Most Common Leukaemia in Adults
Basel, Switzerland (ots/PRNewswire) - - Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera (rituximab) as ...
mehr
30.07.2008 – 22:21
Eli Lilly and Company
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
Chicago (ots/PRNewswire) - - Findings lead to decision to start Phase III pivotal study of LY2062430 in 2009 Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to ...
mehr
29.07.2008 – 13:06
SemBioSys, Genetics Inc
SemBioSys Submits IND for Safflower-Produced Insulin to U.S. FDA
Calgary (ots/PRNewswire) - - Submission Demonstrates Progress of Plant-Derived Insulin Program Scheduled to Enter the Clinic Later This Year SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has submitted an Investigational New Drug ...
mehr
29.07.2008 – 08:08
Valeo Management Services
Valeo: First Half 2008 Results
Paris (ots/PRNewswire) - - Net Income up by 41% - Fourth Consecutive Quarter of Margin Improvement - Debt Reduction of 178 Million Euros - Good Level of Order Intake Valeo's Board of Directors, which met yesterday, approved the consolidated financial summary for the first half 2008. 1st half** Quarterly change in 2008 In million euros 2nd 1st ...
mehr

28.07.2008 – 20:53
Abbott Laboratories
Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System
Dar Es Salaam, Tanzania (ots/PRNewswire) - - Partnership Will Modernize All Regional Hospital Laboratories to Improve Access to Care Across the Country At a ceremony today, the Ministry of Health and Social Welfare, United Republic of Tanzania, and Abbott Fund commemorated the latest step in a nationwide ...
mehr
28.07.2008 – 14:05
GIVENCHY Parfum Paris
Justin Timberlake in Paris for Givenchy
Paris (ots/PRNewswire) - On 24 June, Justin Timberlake made an exclusive appearance in Paris for Parfums Givenchy at the press presentation of Givenchy's new men's fragrance. Timberlake is the face of the new scent, which will go on sale in September 2008, and is featured in the two advertising visuals for the brand. Multimedia News Release - http://www.prnewswire.com/mnr/givenchy/34164/ The American star's ...
mehr
27.07.2008 – 18:37
Saxo Bank (Switzerland) SA
Saxo Bank Founders are Proud of Team CSC Saxo Bank
Paris and Copenhagen, Denmark (ots/PRNewswire) - In a statement following the final results of this year's Tour de France, the two founders of Saxo Bank and joint CEOs, Kim Fournais and Lars Seier Christensen, praised the Team CSC Saxo Bank and said that with this Tour the cycling sport had reached a turning point. "Watching Carlos Sastre in the Yellow Jersey and Andy Schleck in the White, side by side, today, ...
mehr
24.07.2008 – 17:07
Roche Pharmaceuticals
Studies Assessed by European Health Authority Conclude That Impurity in Roche's Viracept(R) (nelfinavir mesylate) Did Not Increase Patient's Risk of Cancer
Basel, Switzerland (ots/PRNewswire) - The European Committee for Human Medicinal Products (CHMP) has confirmed that the presence of an impurity called ethyl methanesulfonate (EMS) in Roche's Viracept (nelfinavir mesylate) did not increase patients' risk of developing cancer. The discovery of the EMS impurity ...
mehr
23.07.2008 – 22:03
ICS Copper Systems Ltd
ICS Copper Drills 40.9 Meters of 1.10% Cu and 16.0 Meters of 1.56% Cu at the Mokambo Property
Abbotsford, British Columbia (ots/PRNewswire) - ICS Copper Systems Ltd. (ICX:TSX.V) is pleased to announce that the Company has obtained important assays and widths from the sulphide twinning confirmation diamond drill program which is now completed. The latest results show that hole m-08-s-04 intersected 40.9 meters true thickness of 1.10% total copper and hole ...
mehr
22.07.2008 – 12:30
Helsinn Healthcare SA
Successful Inspection of Helsinn Birex Pharmaceuticals Dublin, Ireland by the US Food and Drug Administration
Dublin, Ireland (ots) - Helsinn is pleased to announce that Helsinn Birex Pharmaceuticals, its drug facility in Dublin Ireland, has undergone a successful inspection by the US Food and Drug Administration (FDA) without any Form 483 observations. The FDA visit, which lasted 5 days, was a pre-approval inspection ...
mehr

Vorherige64656667686970717273Nächste